Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
NCT07186413Phase 3Active, not recruiting
- Sponsor
- Galderma
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CD5789 cream vehicle in acne vulgaris (2 arms), sponsored by Galderma. Primary endpoints: Percentage of Participants with Investigator Global Assessment (IGA) Success (Face only) at 12 weeks, Change from Baseline to Week 12 in Facial Non-inflammatory Lesion Count and 1 more. Started Sep 2025; status: active, not recruiting.
02
Drugs
CD5789 cream vehicle
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT07186413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07186413.